Orica (ORI) H2 2025 earnings summary

Executive summary

• Achieved record safety performance with zero fatalities and lowest ever serious injury rate; no significant environmental incidents recorded.

• Delivered highest EBIT in 13 years, up 23% to AUD 992 million, with revenue up 6% to AUD 8.1 billion, and double-digit profit growth across all segments and regions, driven by premium products, technology adoption, and commercial discipline.

• All core segments and regions contributed to earnings growth, supported by successful integration of acquisitions and technology deployment.

• Sustainability initiatives led to a 51% reduction in gross scope 1 and 2 emissions from 2019 levels and a 41% net reduction from baseline, with 22% renewable electricity coverage.

Financial highlights

• EBIT rose 23% year-over-year to AUD 992 million; EBITDA up 20% to AUD 1,491 million; net profit before significant items up 32% to AUD 541 million.

• Earnings per share (EPS) increased 29% to AUD 1.118; net operating cash flow up 18% to AUD 949 million; total dividend per share up 21% to AUD 0.57.

• Return on net assets improved to 13.8%; leverage ratio at 1.39x EBITDA, within target range; net debt at AUD 1.9 billion.

• Statutory net profit after tax was AUD 162 million after AUD 379 million in significant items, mainly non-cash impairments and litigation costs.

• Dividend payout ratio at 50%, within the 40–70% target range.

Outlook and guidance

• EBIT growth expected across all segments in FY 2026, with Blasting Solutions supported by improved mix and margin, Digital Solutions by recurring revenue, and Specialty Mining Chemicals by strong gold outlook.

• Depreciation and amortization forecasted at AUD 520–540 million; capital expenditure to remain in line with prior year.

• Ongoing litigation costs forecast at AUD 50–60 million in FY 2026; increased share buy-back of up to AUD 500 million to be completed by March 2026.

• Medium-term EBIT growth outlook upgraded for Digital Solutions and Specialty Mining Chemicals; RONA target range increased to 13.5–15.5%.